<DOC>
	<DOCNO>NCT01503736</DOCNO>
	<brief_summary>The purpose study determine effect optimum dose evaluate safety ferric citrate , administer three time daily ( TID ) immediately meal total daily dose 4 6 gram 56 day , serum phosphate ( PO4 ) level subject end stage renal disease ( ESRD ) .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Placebo-Controlled Phase 3 Study Effects Ferric Citrate Subjects With End Stage Renal Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Age &gt; 18 year diagnosis ESRD On threetimes per week hemodialysis regimen On stable dose phosphatebinding agent least one month prior study entry . If vitamin D supplementation calcitriol , must stable dose least one month prior study entry . Hct &gt; = 20 % Serum Ca level 8 mg/dL 10.5 mg/dL Is pregnant lactate Clinically significant GI disorder Has tertiary hyperparathyroidism immediately postoperative parathyroidectomy ( within first 3 month postop plasma Ca &lt; 7 mg/dL ) ferritin &gt; 800 ng/mL Unstable medical condition unsuitable study opinion investigator Has treat investigational agent within 30 day enrollment Has history document iron allergy hemochromatosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Kidney Diseases</keyword>
	<keyword>Kidney Failure , Chronic</keyword>
	<keyword>Hyperphosphatemia</keyword>
	<keyword>Urologic Diseases</keyword>
	<keyword>Renal Insufficiency , Chronic</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Phosphorus Metabolism Disorders</keyword>
</DOC>